Federal government undermines COVID-19 vaccine development
Canada’s amended Patent Act weakens protections for intellectual property in the life sciences just when rights are vital for mobilizing a rapid response
Read MoreCanada’s amended Patent Act weakens protections for intellectual property in the life sciences just when rights are vital for mobilizing a rapid response
Read MoreThe new trade agreement represents progress for international trade, but crucially, it weakens protections for the biopharma industry
Read MoreCanada must cautiously approach any policy change that puts patients, innovation and innovative industries at risk
Read MoreBoth countries partner with the private sector and expect patients to share the cost of treatment
Read MoreWill likely result in reduced access to new drugs, and delay research and development
Read MoreAs the trade in counterfeit drugs grows, so do the risks to Canadian patients and the costs to legitimate manufacturers
Read MoreProvide biopharmaceutical firms with patent term extensions to recover time lost due to mandatory governmental regulatory and marketing approvals
Read MoreBiologic medicines are difficult and expensive to develop, and Canadia’s weak intellectual property protections are making it even harder
Read More